AirSculpt Technologies, Inc. (AIRS) Earnings Call Analysis

NASDAQ · Healthcare · Medical Care Facilities

Earnings Reports

• AirSculpt Technologies (AIRS) Q1 2026: GLP-1 Procedures Unlock $100M Long-Term Revenue Potential
  May 08, 2026
• Aeroscope Technologies (AIRS) Q4 2025: Skin Removal Pilot Hits 100 Procedures, Unlocking $100M+ Growth Channel
  April 02, 2026
• AirSculpt Technologies (AIRS) Q3 2025: GLP-1 Patient Demand Spurs New Procedure Suite as Revenue Drops 18%
  November 07, 2025
• AirSculpt Technologies (AIRS) Q2 2025: Lead Generation Hits Record Highs as Cost Initiatives Drive 140bps Sequential Margin Gain
  August 01, 2025
• AirSculpt (AIRS) Q1 2025: Lead Volume Up, But 17% Revenue Drop Sets Cautious Recovery Path
  July 06, 2025
• AirSculpt (AIRS) Q3 2024: De Novo Center Count Rises 15% as Conversion Initiatives Take Hold
  November 08, 2024
• AirSculpt Technologies (AIRS) Q2 2024: Same-Store Revenue Falls 17% as Macro Weakness Forces Marketing Pivot
  August 09, 2024
• AirSculpt Technologies (AIRS) Q1 2024: Same-Store Revenue Drops 10% as De Novo Centers Offset Consumer Weakness
  May 10, 2024
• AirSculpt Technologies (AIRS) Q4 2023: 17% Revenue Growth Anchored by De Novo Expansion, Margin Focus Signals Path to $50M EBITDA
  February 27, 2024
• AirSculpt Technologies (AIRS) Q3 2023: De Novo Centers Drive 20% Revenue Growth, Brand Investment Weighs on Margins
  November 10, 2023

Browse all companies